This listing of claims will replace all prior versions, and listing, of claims in the application:

Listing of Claims:

Claims 1-82, 84, 85, 87, 88, 91-99, 103-130, and 142-144 (cancelled)

Claim 83 (currently amended): The ~~A~~ method for the treatment of a flavivirus or pestivirus infection in a host of claim 89, comprising administering an anti-virally effective amount of a compound of Formula V:



(V)

or a pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable carrier or diluent, wherein:

R^1, R^2 and R^3 are independently H; phosphate; stabilized phosphate prodrug; ~~mono-, di- or triphosphate; a stabilized phosphate;~~ acyl; alkyl; sulfonate ester; alkyl or arylalkyl sulfonyl; methanesulfonyl; benzyl, wherein the phenyl group is optionally substituted with one or more substituents; a lipid; a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered *in vivo* is capable of providing a compound wherein R^1, R^2 and R^3 are independently H or phosphate;

X^1 is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, chloro, bromo, fluoro, iodo, OR^4, NR^4NR^5 or SR^4; and

R^4 and R^5 are independently hydrogen, acyl or alkyl.

Claim 86 (currently amended): The ~~A~~ method for the treatment of a flavivirus or pestivirus infection in a host of claim 89, comprising administering an anti-virally effective amount of a compound of Formula X or XI



(X)



(XI)

or a pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable carrier or diluent, wherein:

Base is a pyrimidine base;

R^1, R^2 and R^3 are independently H; phosphate; stabilized phosphate prodrug; ~~mono-, di- or triphosphate; a stabilized phosphate;~~ acyl; alkyl; sulfonate ester; alkyl or arylalkyl sulfonyl; methanesulfonyl; benzyl, wherein the phenyl group is optionally substituted with one or more substituents; a lipid; a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered *in vivo* is capable of providing a compound wherein R^1, R^2 and R^3 are independently H or phosphate;

R^6 is hydroxy, alkyl, azido, cyano, alkenyl, alkynyl, Br-vinyl, -C(O)O(alkyl), -O(acyl), -O(alkyl), -O(alkenyl), chloro, bromo, fluoro, iodo, NO_2, NH_2, -NH(lower alkyl), -NH(acyl), -N(lower alkyl)$_2$, -N(acyl)$_2$;

R^7 is OR^3, hydroxy, alkyl, azido, cyano, alkenyl, alkynyl, Br-vinyl, -C(O)O(alkyl), -O(acyl), -O(alkyl), -O(alkenyl), chlorine, bromine, iodine, NO_2, NH_2, -NH(lower alkyl), -NH(acyl), -N(lower alkyl)$_2$, -N(acyl)$_2$; and

X is O, S, SO_2 or CH_2.

Claim 89 (currently amended): A method for the treatment of a flavivirus or pestivirus infection in a host, comprising administering an anti-virally effective amount of a compound of Formula XVII:



(XVII)

or a pharmaceutically acceptable or prodrug thereof, optionally in a pharmaceutically acceptable carrier or diluent, wherein:

Base is a pyrimidine base;

R^1 and R^2 are independently H; phosphate; stabilized phosphate prodrug; ~~mono-, di- or triphosphate; a stabilized phosphate;~~ acyl; alkyl; sulfonate ester; alkyl or arylalkyl sulfonyl; methane-sulfonyl; benzyl, wherein the phenyl group is optionally substituted with one or more substituents; a lipid; a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered *in vivo* is capable of providing a compound wherein R^1, R^2 and R^3 are independently H or phosphate;

R^6 is hydroxy, alkyl, azido, cyano, alkenyl, alkynyl, Br-vinyl, -C(O)O(alkyl), -O(acyl), -O(alkyl), -O(alkenyl), chloro, bromo, fluoro, iodo, NO_2, NH_2, -NH(lower alkyl), -NH(acyl), -N(lower alkyl)$_2$, -N(acyl)$_2$;

R^7 is OR^2, hydroxy, alkyl, azido, cyano, alkenyl, alkynyl, Br-vinyl, -C(O)O(alkyl), -O(acyl), -O(alkyl), -O(alkenyl), chlorine, bromine, iodine, NO_2, NH_2, -NH(lower alkyl), -NH(acyl), -N(lower alkyl)$_2$, -N(acyl)$_2$;

R^9 is hydrogen, OR^2, hydroxy, alkyl, azido, cyano, alkenyl, alkynyl, Br-vinyl, -C(O)O(alkyl), -O(acyl), -O(alkyl), -O(alkenyl), chlorine, bromine, iodine, NO_2, NH_2, -NH(lower alkyl), -NH(acyl), -N(lower alkyl)$_2$, -N(acyl)$_2$;

Claim 90 (currently amended): The ~~A~~ method for the treatment of a flavivirus or pestivirus infection in a host of claim 89, comprising administering an anti-virally effective amount of a compound of Formula XVIII:



(XVIII)

or a pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable carrier or diluent, wherein:

Base is a pyrimidine base;

R^1 and R^2 are independently H; phosphate; stabilized phosphate prodrug; acyl; alkyl; sulfonate ester; alkyl or arylalkyl sulfonyl; methane-sulfonyl; benzyl, wherein the phenyl group is optionally substituted with one or more substituents; a lipid; a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered *in vivo* is capable of providing a compound wherein R^1 and R^2 are independently H or phosphate;

R^7 is ~~hydrogen~~, OR^2, alkyl, alkenyl, alkynyl, Br-vinyl, O-alkenyl, chlorine, bromine, iodine, NO_2, amino, -NH(lower alkyl), -NH(acyl), -N(lower alkyl)$_2$, or -N(acyl)$_2$, ~~loweralkylamino, or di(loweralkyl)amino~~;

R^9 is OR^2, alkyl, alkenyl, alkynyl, Br-vinyl, O-alkenyl, chlorine, bromine, iodine, NO_2, amino, -NH(lower alkyl), -NH(acyl), -N(lower alkyl)$_2$, or -N(acyl)$_2$, ~~loweralkylamino, or di(loweralkyl)amino;~~

R^6 and R^8 are H, alkyl, chlorine, bromine or iodine; and

X is O, S, SO_2 or CH_2.

Claim 100 (currently amended): A method for the treatment of a flavivirus or pestivirus infection in a host, comprising administering an antivirally effective amount of a compound of the structure:



or a pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable carrier or diluent.

Claim 101 (currently amended): A method for the treatment of a flavivirus or pestivirus infection in a host, comprising administering an antivirally effective amount of a compound of the structure:



or a pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable carrier or diluent.

Claim 102 (currently amended): A method for the treatment of a flavivirus or pestivirus infection in a host, comprising administering an antivirally effective amount of a compound of the structure:



or a pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable carrier or diluent.

Claim 131 (currently amended): The method ~~of claims~~ of any one of claims 83, 86, 89, 90, 100, 101, 102, or 148-150 ~~130~~, wherein the pharmaceutically acceptable carrier is suitable for oral delivery.

Claim 132 (currently amended): The method ~~of claim 130~~ of any one of claims 83, 86, 89, 90, 100, 101, 102, or 148-150, wherein the pharmaceutically acceptable carrier is suitable for intravenous delivery.

Claim 133 (currently amended): The method ~~of claim 130~~ of any one of claims 83, 86, 89, 90, 100, 101, 102, or 148-150, wherein the pharmaceutically acceptable carrier is suitable for parenteral delivery.

Claim 134 (currently amended): The method ~~of claim 130~~ of any one of claims 83, 86, 89, 90, 100, 101, 102, or 148-150, wherein the pharmaceutically acceptable carrier is suitable for intradermal delivery.

Claim 135 (currently amended): The method ~~of claim 130~~ of any one of claims 83, 86, 89, 90, 100, 101, 102, or 148-150, wherein the pharmaceutically acceptable carrier is suitable for subcutaneous delivery.

Claim 136 (currently amended): The method ~~of claim 130~~ of any one of claims 83, 86, 89, 90, 100, 101, 102, or 148-150, wherein the pharmaceutically acceptable carrier is suitable for topical delivery.

Claim 137 (currently amended): The method ~~of claim 130~~ of any one of claims 83, 86, 89, 90, 100, 101, 102, or 148-150, wherein the compound is in the form of a dosage unit.

Claim 138 (previously added): The method of claim 137, wherein the dosage unit contains 10 to 1500 mg of the compound.

Claim 139 (previously added): The method of claim 137, wherein the dosage unit is a tablet or capsule.

Claim 140 (previously added): The method of claim 138, wherein the dosage unit is a tablet or capsule.

Claim 141 (currently amended): The method of any one of claims ~~82-90, 94-96, 100-102 and 130-40,~~ 83, 86, 89, 90, 100, 101, or 102, wherein the host is a human.

Claim 145 (currently amended): A method for the treatment of a flavivirus or pestivirus infection in a human, comprising administering an antivirally effective amount of a compound of the structure:



or a pharmaceutically acceptable salt or ester thereof.

Claim 146 (currently amended): A method for the treatment of a flavivirus or pestivirus infection in a human, comprising administering an antivirally effective amount of a compound of the structure:



or a pharmaceutically acceptable salt or ester thereof.

Claim 147 (currently amended): A method for the treatment of a flavivirus or pestivirus infection in a human, comprising administering an antivirally effective amount of a compound of the structure:



or a pharmaceutically acceptable salt or ester thereof

Claim 148 (new): A method for the treatment of a flavivirus or pestivirus infection in a human, comprising administering an antivirally effective amount of a compound of the structure:



or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier.

Claim 149 (new): A method for the treatment of a flavivirus or pestivirus infection in a human, comprising administering an antivirally effective amount of a compound of the structure:



or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier or diluent.

Claim 150 (new): A method for the treatment of a flavivirus or pestivirus infection in a human, comprising administering an antivirally effective amount of a compound of the structure:



or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier or diluent.

Claim 151 (new): The method of any one of claim 83, 86, 89, 90, 100, 101, 102, or 148-150, wherein the pestivirus or flavivirus is bovine viral diarrhea virus (BVDV).

Claim 152 (new): The method of any one of claim 83, 86, 89, 90, 100, 101, 102, or 148-150, wherein the pestivirus or flavivirus is a Dengue virus.

Claim 153 (new): The method of any one of claim 83, 86, 89, 90, 100, 101, 102, or 148-150, wherein the pestivirus or flavivirus is a West Nile virus.

Claim 154 (new): The method of any one of claim 83, 86, 89, 90, 100, 101, 102, or 148-150, wherein the pestivirus or flavivirus is a yellow fever virus.